Takeda's myeloma drug ixazomib is 'most important' launch expected in 2016
This article was originally published in Scrip
Executive Summary
The European Medicines Agency earlier this week granted accelerated assessment to Takeda Pharmaceutical's late-stage multiple myeloma therapy, ixazomib, and the drug maker has big plans for its latest cancer product.